Research Topics
| P L GiangrandeSummaryAffiliation: University of Oxford Country: UK Publications
| Collaborators
|
Detail Information
Publications
Haemophilia B: Christmas diseasePaul Giangrande
Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, OX3 7LJ, UK
Expert Opin Pharmacother 6:1517-24. 2005..Trials of gene therapy are also underway, but these are in the very early stages and will not be a realistic option for at least another 20 years...- Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reactionN S Curry
Oxford Haemophilia Centre and Thrombosis Unit, Oxford Radcliffe Hospitals, Oxford, UK
Haemophilia 13:328-30. 2007..Immune tolerance was achieved by desensitisation with escalating doses of factor IX followed by the Malmö regimen... 
Management of difficult-to-treat inhibitor patientsP L F Giangrande
Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, UK
Haemophilia 16:52-7. 2010..Delegate opinions on the best treatment option for each scenario are described together with actual treatment given in real-life cases and its outcome...- Gene therapy for hemophilia? NoP L F Giangrande
Oxford Haemophilia Centre, Thrombosis Unit, Churchill Hospital, Oxford OX3 7LK, UK
J Thromb Haemost 2:1236-7. 2004 - Blood products for hemophilia: past, present and futurePaul L F Giangrande
Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, UK
BioDrugs 18:225-34. 2004..Transgenic animals are a potential source of therapeutic materials. Several trials of gene therapy for hemophilia are already underway... - Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitorsP L F Giangrande
Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, UK
Haemophilia 15:501-8. 2009..Although the initial cost of product to cover surgery such as arthroplasty is high, it needs to be borne in mind that this may be offset in subsequent years by savings resulting from avoidance of bleeding episodes in the affected joint... - Treatment of patients with haemophilia and inhibitory antibodiesP L F Giangrande
Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, UK
Indian J Pediatr 70:655-9. 2003..It is possible to suppress antibody production with immune tolerance, which is successful in approximately 85% of cases and relapse is rare... - Treatment of hemophilia: recombinant factors only? YesP L F Giangrande
Oxford Haemophilia Centre, Churchill Hospital, Oxford, UK
J Thromb Haemost 1:214-5. 2003 - Six characters in search of an author: the history of the nomenclature of coagulation factorsPaul L F Giangrande
Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, UK
Br J Haematol 121:703-12. 2003 - Adverse events in the prophylaxis of haemophiliaP L F Giangrande
Oxford Haemophilia Centre and Thrombosis Unit, The Churchill Hospital, Oxford, UK
Haemophilia 9:50-4; discussion 55-6. 2003..Whilst sporting activities are to be encouraged, there is a potential for significant trauma in children with prophylaxis, as plasma coagulation factor levels remain far below normal with the usual regimens... - The WFH Haemophilia Centre Twinning Programme: 10 years of growth, 1993-2003P L F Giangrande
World Federation of Haemophilia, Montreal, Quebec, Canada
Haemophilia 9:240-4. 2003..In addition, continuing support and advice are available from the WFH regional programme officers... - Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIIIP L F Giangrande
Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, UK
Haemophilia 8:798-801. 2002..In conclusion, there was no evidence of transmission of PPR or other marker porcine virus associated with the use of porcine FVIII concentrate (Hyate: C)... - Air travel and thrombosisPaul L F Giangrande
Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford OX3 7LJ, UK
Br J Haematol 117:509-12. 2002 - World Federation of Haemophilia programs in developing countriesPaul L F Giangrande
World Federation of Haemophilia, Montreal, Quebec, Canada
Semin Thromb Hemost 31:555-60. 2005..The WFH is also involved in fostering discussion on key issues such as safety and supply of blood products... - Safety and efficacy of KOGENATE Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs)P L F Giangrande
Oxford Haemophilia Centre, Churchill Hospital, Oxford, UK
Haemophilia 8:19-22. 2002..The incidence of inhibitor formation is not different to that observed with other recombinant or plasma-derived products... - Variation in inhibitor reactivity in acquired haemophilia A with different concentratesK Sukhu
Oxford Haemophilia Centre, The Churchill Hospital, Oxford, UK
Clin Lab Haematol 22:287-90. 2000..All but one antibody had very low reactivity with porcine FVIII. Further work will be required to establish whether concentrates manifesting a low level of in vitro reactivity with the inhibitor have a better haemostatic effect in vivo... - Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIVSarah C Darby
Clinical Trial Service Unit, University of Oxford, Oxford, UK
Blood 110:815-25. 2007..There was no evidence of any death from variant Creutzfeldt-Jakob disease or from conditions that could be confused with it... - The impact of HIV on mortality rates in the complete UK haemophilia populationSarah C Darby
AIDS 18:525-33. 2004..From 1997, after the introduction of effective treatment, substantial reductions occurred, although mortality from liver disease remained high...